Carey Anders, Edward Neuberger, Naomi R M Schwartz, Karen Bartley, Shu Wang, Yutong Liu, Brian T Pittner, Peter A Kaufman, Jane Meisel
{"title":"图卡替尼治疗her2阳性转移性乳腺癌患者的实际治疗模式和临床结果：两个全国性行政健康声明数据库的分析","authors":"Carey Anders, Edward Neuberger, Naomi R M Schwartz, Karen Bartley, Shu Wang, Yutong Liu, Brian T Pittner, Peter A Kaufman, Jane Meisel","doi":"10.1007/s10147-025-02800-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To describe real-world characteristics and clinical outcomes among patients with HER2+ MBC receiving tucatinib-based treatments.</p><p><strong>Methods: </strong>This retrospective study included patients diagnosed with HER2+ MBC between January 2017 and December 2022 from two administrative health claims databases, Merative<sup>TM</sup>MarketScan<sup>®</sup> and the Komodo Healthcare Map<sup>™</sup>. Patient characteristics were captured at baseline (≤ 6 months prior to tucatinib initiation). Outcomes were assessed starting from tucatinib-based treatment initiation and included real-world time to discontinuation (rwTTD) and treatment persistence.</p><p><strong>Results: </strong>There were 150 patients in MarketScan<sup>®</sup> who received tucatinib-based therapy: median (IQR) prior lines of therapy (LOT) was 2 (2-4) and 110 patients (73.3%) had brain metastases. 436 patients in Komodo<sup>™</sup> received tucatinib-based therapy: median (IQR) prior LOTs were 2 (1-3), and 307 (70.4%) had brain metastases. Median (95% CI) rwTTD was 7.4 (5.0-13.1) months in MarketScan<sup>®</sup> (median follow-up 9.7 months) and 9.0 (7.4-9.8) months in Komodo<sup>™</sup> (median follow-up 10.3 months). In patients who received tucatinib in combination with trastuzumab and capecitabine immediately following trastuzumab deruxtecan (T-DXd) and after ≥ 2 prior HER2-directed therapies (MarketScan<sup>®</sup>: n = 26, median prior LOT 4; Komodo: n = 34, median prior LOT 3), median (95% CI) rwTTD was 5.5 (3.4-not reached [NR]) months in MarketScan<sup>®</sup> and 4.8 (3.2-NR) months in Komodo.</p><p><strong>Conclusion: </strong>These results reinforce the real-world effectiveness of tucatinib in patients with HER2+ MBC, including patients with prior T-DXd treatment. Further research is needed to determine the optimal treatment sequencing for patients with HER2+ MBC.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":"1982-1991"},"PeriodicalIF":2.8000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474727/pdf/","citationCount":"0","resultStr":"{\"title\":\"Real-world treatment patterns and clinical outcomes with tucatinib-based therapy in patients with HER2-positive metastatic breast cancer: analyses of two nationwide administrative health claims databases.\",\"authors\":\"Carey Anders, Edward Neuberger, Naomi R M Schwartz, Karen Bartley, Shu Wang, Yutong Liu, Brian T Pittner, Peter A Kaufman, Jane Meisel\",\"doi\":\"10.1007/s10147-025-02800-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To describe real-world characteristics and clinical outcomes among patients with HER2+ MBC receiving tucatinib-based treatments.</p><p><strong>Methods: </strong>This retrospective study included patients diagnosed with HER2+ MBC between January 2017 and December 2022 from two administrative health claims databases, Merative<sup>TM</sup>MarketScan<sup>®</sup> and the Komodo Healthcare Map<sup>™</sup>. Patient characteristics were captured at baseline (≤ 6 months prior to tucatinib initiation). Outcomes were assessed starting from tucatinib-based treatment initiation and included real-world time to discontinuation (rwTTD) and treatment persistence.</p><p><strong>Results: </strong>There were 150 patients in MarketScan<sup>®</sup> who received tucatinib-based therapy: median (IQR) prior lines of therapy (LOT) was 2 (2-4) and 110 patients (73.3%) had brain metastases. 436 patients in Komodo<sup>™</sup> received tucatinib-based therapy: median (IQR) prior LOTs were 2 (1-3), and 307 (70.4%) had brain metastases. Median (95% CI) rwTTD was 7.4 (5.0-13.1) months in MarketScan<sup>®</sup> (median follow-up 9.7 months) and 9.0 (7.4-9.8) months in Komodo<sup>™</sup> (median follow-up 10.3 months). In patients who received tucatinib in combination with trastuzumab and capecitabine immediately following trastuzumab deruxtecan (T-DXd) and after ≥ 2 prior HER2-directed therapies (MarketScan<sup>®</sup>: n = 26, median prior LOT 4; Komodo: n = 34, median prior LOT 3), median (95% CI) rwTTD was 5.5 (3.4-not reached [NR]) months in MarketScan<sup>®</sup> and 4.8 (3.2-NR) months in Komodo.</p><p><strong>Conclusion: </strong>These results reinforce the real-world effectiveness of tucatinib in patients with HER2+ MBC, including patients with prior T-DXd treatment. Further research is needed to determine the optimal treatment sequencing for patients with HER2+ MBC.</p>\",\"PeriodicalId\":13869,\"journal\":{\"name\":\"International Journal of Clinical Oncology\",\"volume\":\" \",\"pages\":\"1982-1991\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12474727/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10147-025-02800-7\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/8/6 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-025-02800-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Real-world treatment patterns and clinical outcomes with tucatinib-based therapy in patients with HER2-positive metastatic breast cancer: analyses of two nationwide administrative health claims databases.
Purpose: To describe real-world characteristics and clinical outcomes among patients with HER2+ MBC receiving tucatinib-based treatments.
Methods: This retrospective study included patients diagnosed with HER2+ MBC between January 2017 and December 2022 from two administrative health claims databases, MerativeTMMarketScan® and the Komodo Healthcare Map™. Patient characteristics were captured at baseline (≤ 6 months prior to tucatinib initiation). Outcomes were assessed starting from tucatinib-based treatment initiation and included real-world time to discontinuation (rwTTD) and treatment persistence.
Results: There were 150 patients in MarketScan® who received tucatinib-based therapy: median (IQR) prior lines of therapy (LOT) was 2 (2-4) and 110 patients (73.3%) had brain metastases. 436 patients in Komodo™ received tucatinib-based therapy: median (IQR) prior LOTs were 2 (1-3), and 307 (70.4%) had brain metastases. Median (95% CI) rwTTD was 7.4 (5.0-13.1) months in MarketScan® (median follow-up 9.7 months) and 9.0 (7.4-9.8) months in Komodo™ (median follow-up 10.3 months). In patients who received tucatinib in combination with trastuzumab and capecitabine immediately following trastuzumab deruxtecan (T-DXd) and after ≥ 2 prior HER2-directed therapies (MarketScan®: n = 26, median prior LOT 4; Komodo: n = 34, median prior LOT 3), median (95% CI) rwTTD was 5.5 (3.4-not reached [NR]) months in MarketScan® and 4.8 (3.2-NR) months in Komodo.
Conclusion: These results reinforce the real-world effectiveness of tucatinib in patients with HER2+ MBC, including patients with prior T-DXd treatment. Further research is needed to determine the optimal treatment sequencing for patients with HER2+ MBC.
期刊介绍：
The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
